Are PCSK9 Inhibitors Potentially Appropriate for Patients With Mixed Hyperlipidemia and High Cardiovascular Risk, Despite Statins?
PCSK9 inhibitors are a new class of drugs, not yet FDA-approved, that have been shown to dramatically lower LDL cholesterol levels. Three clinicians discuss their potential. Video includes comments by Dylan Steen, MD, Department of Internal Medicine, Division of Cardiovascular Health and Disease, and UC Health cardiologist. View the video.
Leave a reply →